Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perinatal/Neonatal Case Presentation
  • Published:

Perinatal/Neonatal Case Presentation

Administration of rituximab during the first trimester of pregnancy without consequences for the newborn

Journal of Perinatology volume 26, pages 252–255 (2006)Cite this article

Abstract

Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M . Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29 (Suppl 2): 105–112.

    Article  CAS  PubMed  Google Scholar 

  2. MabThera: Summary of products characteristics (online). Available from URL: http://www.emea.eu.int/#.

  3. McLaughin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    Article  Google Scholar 

  4. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood 1994; 84: 2457–2466.

    CAS  PubMed  Google Scholar 

  5. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435–445.

    CAS  PubMed  Google Scholar 

  6. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106.

    Article  CAS  PubMed  Google Scholar 

  7. Mc Keever KR, Beyer J, Ortega S, Combs D, Tsusaki H . An embryo-fetal development study in cynomolgus monkeys with rituximab, an anti-CD20 antibody (abstract). Toxicol Sci 2003; 72 (Suppl): 172.

    Google Scholar 

  8. Herold M, Schnohr S, Bittrich H . Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19: 3439.

    Article  CAS  PubMed  Google Scholar 

  9. Kimby E, Sverrisdottir A, Elinder G . Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004; 72: 292–295.

    Article  PubMed  Google Scholar 

  10. Roitt I, Brostoff J, Male D . Immunology. Harcourt Publishers Limited: London, 2001, pp 65–85.

    Google Scholar 

  11. Oxelius VA . IgG subclasses levels in infancy and childhood. Acta Paediatr Scand 1979; 68: 23–27.

    Article  CAS  PubMed  Google Scholar 

  12. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A . Treatment of childhood autoimmune haemolytic anemia with rituximab. Lancet 2001; 358: 1511–1513.

    Article  CAS  PubMed  Google Scholar 

  13. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001.

    Article  CAS  PubMed  Google Scholar 

  14. van der Kolk LE, Baars JW, Prins MH, van Oers MH . Rituximab treatment results in impaired secondary humoral immune response. Blood 2002; 6: 2257–2259.

    Google Scholar 

  15. Goldman AS, Ham Pong AJ, Goldblum RM . Host defences: development and maternal contributions. Adv Pediatr 1985; 32: 71–100.

    CAS  PubMed  Google Scholar 

  16. Ferguson AC, Cheung SS . Modulation of immunoglobulin M and G synthesis by monocytes and T lymphocytes in the newborn infant. J Pediatr 1981; 98: 385–391.

    Article  CAS  PubMed  Google Scholar 

  17. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM . Expression of human B-cell associated antigens on leukemias and lymhomas: a model of human B cell differentiation. Blood 1984; 63: 1424–1433.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mrs Juliette Baur for her excellent assistance in preparing this manuscript

Author information

Authors and Affiliations

  1. Département d'Hématologie, Hôpital Emile Muller, Mulhouse Cedex, France

    M Ojeda-Uribe, G Jung & B Drenou

  2. Fédération de Gynécologie-Obstétrique, Hôpital Emile Muller, Mulhouse Cedex, France

    C Gilliot

  3. Unité d'Hémovigilance – Biovigilance, Hôpital Emile Muller, Mulhouse Cedex, France

    A Brunot

Authors
  1. M Ojeda-Uribe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Gilliot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Drenou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Brunot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Ojeda-Uribe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ojeda-Uribe, M., Gilliot, C., Jung, G. et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 26, 252–255 (2006). https://doi.org/10.1038/sj.jp.7211481

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211481

Keywords

This article is cited by

Search

Advanced search

Quick links